Heart failure drug could 'cut deaths by a fifth'

Conclusion This was a well conducted study that achieved impressive results. In this 27 month-long randomised controlled trial of 8,442 people with heart failure and an ejection fraction of 40% or less, compared to enalpril, the new drug LCZ696: reduced the risk of death from cardiovascular disease or the risk of hospitalisation for heart failure by 20% reduced the risk of death from cardiovascular disease by 20% reduced the risk of hospitalisation for heart failure by 21% reduced the risk of death from any cause by 16% Marketing authorisation is now required before it can be sold. The developer of the drug, Novartis, states that they plan to file the application for marketing authorisation in the European Union in early 2015. It is currently unclear how much LCZ696 will cost. Until this information becomes available, it is difficult to predict whether LCZ696 will be offered by the NHS. Analysis by Bazian. Edited by NHS Choices. Follow Behind the Headlines on Twitter. Join the Healthy Evidence forum. Links To The Headlines New heart drug LCZ696 could reduce heart failure deaths by 20%, scientists say. The Independent, August 30 2014 'Remarkable' new heart drug will cut deaths by a fifth - and could be available as early as next year. Mail Online, September 1 2014 New heart drug will cut deaths by a fifth. The Daily Telegraph, August 30 2014 Links To Science McMurray JJV, Packer M, Desai AS, et al. Angiotensin–Neprilysin Inhibition versus Enalapril i...
Source: NHS News Feed - Category: Consumer Health News Tags: Heart/lungs Source Type: news